Omar Nadeem, Myeloma Physician and Clinical Investigator, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, shared a post on LinkedIn:
“Pleased to share that the editors at Nature Communications have featured our study of ‘Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study’ in the Editors’ Highlights section.”
Title: Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Authors: Omar Nadeem, Michelle Aranha, Robert Redd, Michael Koontz, Jeffrey Matous, Andrew Yee, Jeffrey Zonder, Andrew Kin, Sophie Magidson, Elizabeth Lightbody, Ting Wu, Floris Chabrun, Jean-Baptiste Alberge, Ankit Dutta, Jacqueline Perry, Ashlee Sturtevant, Mahshid Rahmat, Junko Tsuji, Christine Davie, Caroline Ricciardi, Frances Arters, Marjorie Marto, Amy Bergeron, Jacalyn Rosenblatt, Elizabeth O’Donnell, Tarek Mouhieddine, Lorena Pantano, Jacob Laubach, Paul Richardson, Gad Getz, Lorenzo Trippa, Romanos Sklavenitis-Pistofidis, Irene Ghobrial
Other articles about Daratumumab on OncoDaily.